Correction: The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.

Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
May 2019
Historique:
pubmed: 10 5 2019
medline: 10 5 2019
entrez: 10 5 2019
Statut: ppublish

Résumé

The original version of this article contained an error in Fig. 5a where the colours of the labels representing the Hinge and LBD of the AR were incorrect and did not match the corresponding exons. The corrected version of this Figure now appears in the article. The conclusions of this paper were not affected. The authors apologise for this error and any confusion caused.

Identifiants

DOI: 10.1038/s41388-019-0826-2 PMID: 31068666 PMC: PMC7608372
pubmed: 31068666
doi: 10.1038/s41388-019-0826-2
pii: 10.1038/s41388-019-0826-2
pmc: PMC7608372
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

4425

Commentaires et corrections

Type : ErratumFor

Auteurs

A C Hepburn (AC)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. anastasia.hepburn@newcastle.ac.uk.

R E Steele (RE)

Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer, Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, BT9 7AE, UK.

R Veeratterapillay (R)

Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK.

L Wilson (L)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

E E Kounatidou (EE)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

A Barnard (A)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

P Berry (P)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

J R Cassidy (JR)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

M Moad (M)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

A El-Sherif (A)

Department of Pathology, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.

L Gaughan (L)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

I G Mills (IG)

Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer, Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, BT9 7AE, UK.
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 9DU, UK.

C N Robson (CN)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. c.n.robson@newcastle.ac.uk.
ORCID: 0000-0002-9628-6669

R Heer (R)

Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. rakesh.heer@newcastle.ac.uk.
Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK. rakesh.heer@newcastle.ac.uk.
ORCID: 0000-0003-1952-7462

Classifications MeSH